Capricor Therapeutics, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Capricor Therapeutics (NasdaqGS:CAPR) has filed a lawsuit to rescind its U.S. distribution agreement for deramiocel, its Duchenne muscular dystrophy therapy, with NS Pharma and Nippon Shinyaku. The company argues that flaws in the pricing terms could restrict patient access to deramiocel in the U.S. market. In parallel, Capricor is preparing for potential direct commercialization, including plans to expand manufacturing capacity and strengthen its leadership team. Deramiocel has completed a...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $60 price target.
Capricor Therapeutics Inc (CAPR) reports a robust cash reserve and promising trial results, but faces hurdles with increased expenses and a legal dispute impacting its commercialization plans.
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call May 12, 2026 4:30 PM EDTCompany ParticipantsAnthony Bergmann - CFO & Corporate TreasurerLinda...
Presentation Operator MessageOperator Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics First Quarter 2026 Conference Call. [Operator Instructions] This call is being...
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku. On t
Capricor Therapeutics (CAPR) reported Q1 2026 revenue of $0.0M and a wider-than-expected EPS loss of -$0.59. Focus is on the August 22 PDUFA date for deramiocel, a DMD cell therapy, with shares up slightly after hours.
Capricor Therapeutics Inc:Capricor Therapeutics reports first quarter 2026 financial results and provides corporate update Capricor Therapeutics Inc - no revenue recognized for Q1 2026 or Q1...
SAN DIEGO — SAN DIEGO — Capricor Therapeutics Inc. on Tuesday reported a loss of $33.9 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 59...
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.
Focused on advanced cell therapies for rare diseases, this biotech firm reported a notable insider sale in its latest SEC filing.
Capricor Therapeutics (CAPR) is back in focus after releasing Phase 3 HOPE-3 data for its Duchenne muscular dystrophy therapy Deramiocel, alongside an ongoing FDA review with an August 22, 2026 target decision date. See our latest analysis for Capricor Therapeutics. That Phase 3 HOPE-3 update appears to sit alongside strong momentum, with a 90 day share price return of 37.3% and a very large 1 year total shareholder return, while the 1 day share price move was slightly negative. If you are...
Capricor sued Nippon Shinyaku over Deramiocel distribution terms, citing pricing issues and patient access risks.
Capricor Therapeutics, Inc. (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it has filed a lawsuit against Nippon Shinyaku Co.,
– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 -- Capricor Therapeutics , a biotechnology company developing transformative cell and...
Capricor Therapeutics recently presented data from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne muscular dystrophy at the 2026 American Academy of Neurology meeting, highlighting statistically and clinically meaningful preservation of upper limb function supported by real-world video assessments of self-feeding ability. The combination of late-stage efficacy data and an ongoing Biologics License Application review with an August 22, 2026 PDUFA date underscores Deramiocel’s potential...
Just because a business does not make any money, does not mean that the stock will go down. For example, Capricor...
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 2.18M | $66.33M | 0.00% | Added+163.0% | 2026-03-31 |
| Citadel | multi-strat | 821.2K | $24.96M | 0.03% | Trimmed-55.4% | 2026-03-31 |
| FidelityFMR | fundamental | 772.6K | $23.49M | 0.00% | Trimmed-16.3% | 2026-03-31 |
| Wellington | fundamental | 108.6K | $3.30M | 0.00% | Trimmed-15.3% | 2026-03-31 |
| TwoSigma | quant | 30.9K | $940.33K | 0.00% | Trimmed-43.5% | 2026-03-31 |
| TRowePrice | fundamental | 31.0K | $943 | 0.00% | Added+33.9% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-11upcoming | -0.59 | — | — |
| 2026-03-12 | -0.55 | -0.62 | -12.43% |
| 2025-11-10 | -0.54 | -0.54 | +0.26% |
| 2025-08-11 | -0.48 | -0.57 | -19.37% |
| 2025-05-13 | -0.32 | -0.53 | -66.67% |
| 2025-03-19 | -0.09 | -0.16 | -70.21% |
| 2024-11-13 | -0.34 | -0.38 | -12.59% |
| 2024-08-07 | -0.33 | -0.35 | -5.00% |
| 2024-05-13 | -0.11 | -0.31 | -173.54% |
| 2024-02-29 | -0.09 | -0.02 | +72.22% |
| 2023-11-14 | -0.27 | -0.25 | +8.41% |
| 2023-08-07 | -0.33 | -0.29 | +12.12% |
| 2023-05-11 | -0.32 | -0.31 | +3.13% |
| 2023-03-15 | -0.34 | -0.31 | +10.15% |
| 2022-11-10 | -0.32 | -0.26 | +18.75% |
| 2022-08-10 | -0.25 | -0.29 | -13.73% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CAPR | -3.07% | +15.94% | +3.81% | +202.93% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -6.04% | +20.58% | +7.25% | +190.24% |